COVID-19 therapeutics to include a “conditional recommendation" on Merck & Co's Covid drug Molnupiravir, a new antiviral medicine.
Under this conditional approval, Merck's Covid-19 antiviral pill was approved for patients who are in the early stages of the disease.WHO has updated its living guidelines on #COVID19 therapeutics to include a conditional recommendation on molnupiravir, a new antiviral medicine.https://t.co/ZRygSEAbzC As per the global health body, Molnupiravir should only be “provided to non-severe COVID-19 patients" with the highest risk of hospitalisation.
Patients who come in this category are those who have not received a COVID-19 vaccination, older people, people with immunodeficiencies and people living with chronic diseases like diabetes.
As this is a new drug, the WHO has recommended active monitoring for drug safety, along with other strategies to mitigate potential harms. “Children, pregnant and breastfeeding women should not be given the drug.